CL2012000947A1 - Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis. - Google Patents
Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.Info
- Publication number
- CL2012000947A1 CL2012000947A1 CL2012000947A CL2012000947A CL2012000947A1 CL 2012000947 A1 CL2012000947 A1 CL 2012000947A1 CL 2012000947 A CL2012000947 A CL 2012000947A CL 2012000947 A CL2012000947 A CL 2012000947A CL 2012000947 A1 CL2012000947 A1 CL 2012000947A1
- Authority
- CL
- Chile
- Prior art keywords
- sodium
- pharmaceutical composition
- microlin
- rhinitis
- asthma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulación de suspensión en aerosol que comprende A) Fumarato de formoterol micronizado, B) Propionato de fluticasona micronizado, C) Cantidad subterapéutica de un excipiente depurador de humedad que comprende cromolin sodio y D) propulsor HFA; composicion farmacéutica; método para incrementar la estabilidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0918149.6A GB0918149D0 (en) | 2009-10-16 | 2009-10-16 | Improved medicinal aerosol formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012000947A1 true CL2012000947A1 (es) | 2012-12-14 |
Family
ID=41462450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012000947A CL2012000947A1 (es) | 2009-10-16 | 2012-04-13 | Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis. |
Country Status (26)
Country | Link |
---|---|
US (3) | US20120282189A1 (es) |
EP (3) | EP4327807A3 (es) |
JP (5) | JP2013507430A (es) |
CN (1) | CN102665675B (es) |
AU (1) | AU2010305698C9 (es) |
BR (1) | BR112012008983A2 (es) |
CA (1) | CA2776359C (es) |
CL (1) | CL2012000947A1 (es) |
CY (1) | CY1116109T1 (es) |
DK (2) | DK2488158T3 (es) |
ES (1) | ES2533372T3 (es) |
FI (1) | FI2881108T3 (es) |
GB (1) | GB0918149D0 (es) |
HK (2) | HK1173077A1 (es) |
HR (1) | HRP20150174T1 (es) |
IL (1) | IL219161B (es) |
LT (1) | LT2881108T (es) |
MX (1) | MX2012004337A (es) |
NZ (1) | NZ599901A (es) |
PL (1) | PL2488158T3 (es) |
PT (2) | PT2488158E (es) |
RS (2) | RS65391B1 (es) |
SI (2) | SI2488158T1 (es) |
SM (1) | SMT201500052B (es) |
WO (1) | WO2011045432A1 (es) |
ZA (1) | ZA201202452B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ528640A (en) * | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
TWI495466B (zh) * | 2010-09-23 | 2015-08-11 | Intech Biopharm Ltd | 用於氣喘之吸入性複方組合物 |
GB201515310D0 (en) * | 2015-08-27 | 2015-10-14 | Jagotec Ag | Pharmaceutical composition |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2503962A1 (de) | 1975-01-31 | 1976-08-05 | Thomae Gmbh Dr K | Spruehbare mittel in suspensionsform zur anwendung auf der haut |
FR2420972A1 (fr) | 1978-03-31 | 1979-10-26 | Roussel Uclaf | Application du peroxyde de thenoyle a titre de medicament |
JPS5529524A (en) | 1978-08-21 | 1980-03-01 | Toyo Aerosol Kogyo Kk | Powdery aerosol composition |
DE2914181C2 (de) | 1979-04-07 | 1982-06-16 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Verfahren und Vorrichtung zum Trocknen temperaturempfindlicher Güter der Pharma- und Nahrungsmittelindustrie |
JPS6135815A (ja) | 1984-07-28 | 1986-02-20 | Sanshin Seisakusho:Kk | 上部集液式加圧ろ過機に於ける機体内液の脱液方法及び同装置 |
FR2666962B1 (fr) | 1990-09-26 | 1996-06-14 | Oreal | Composition antifongique sous forme de spray sec. |
US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
ATE150296T1 (de) * | 1991-12-18 | 1997-04-15 | Minnesota Mining & Mfg | Aerosolzusammensetzungen für arzneimittelsuspensionen |
DE4321288A1 (de) | 1993-06-26 | 1995-01-05 | Solvay Fluor & Derivate | Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen |
US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
DE69432224T2 (de) | 1993-12-02 | 2003-12-04 | Abbott Lab | Aerosole als darreichungsform mit cfc-freiem treibmittel |
NZ306280A (en) | 1995-04-14 | 1999-07-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol |
JP3707107B2 (ja) | 1995-09-18 | 2005-10-19 | 鈴木油脂工業株式会社 | 薬剤分散液及びその製造方法 |
US6054488A (en) | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
WO1998033479A1 (en) | 1997-01-30 | 1998-08-06 | Alpenstock Holdings Limited | Haemostatic aerosol composition |
AU718967B2 (en) | 1997-02-05 | 2000-05-04 | Jagotec Ag | Medical aerosol formulations |
US6086376A (en) | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
EP1100465B1 (de) | 1998-07-24 | 2004-11-24 | Jago Research Ag | Medizinische aerosolformulierungen |
US6475467B1 (en) | 1998-08-04 | 2002-11-05 | Jago Research Ag | Medicinal aerosol formulations |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
PT1283036E (pt) | 1998-11-13 | 2008-03-06 | Jagotec Ag | Inalador de pó seco de dose múltipla com um reservatório de pó |
US7074388B2 (en) * | 1998-12-10 | 2006-07-11 | Kos Life Science, Inc. | Water stabilized medicinal aerosol formulation |
US6926911B1 (en) | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
WO2000047203A1 (en) | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
GB9903759D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
ME00220B (me) | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom |
US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
AU2001247123A1 (en) * | 2000-07-19 | 2002-02-05 | Aeropharm Technology, Inc. | A medicinal aerosol formulation |
CA2417973A1 (en) | 2000-08-04 | 2002-02-14 | Longwood Pharmaceutical Research, Inc. | Formulations of mometasone and a bronchodilator for pulmonary administration |
AU1131102A (en) | 2000-10-09 | 2002-04-22 | 3M Innovative Properties Co | Medicinal aerosol formulations |
NZ528640A (en) | 2001-03-30 | 2004-06-25 | Jagotec Ag | Medical aerosol formulations |
US6455028B1 (en) | 2001-04-23 | 2002-09-24 | Pharmascience | Ipratropium formulation for pulmonary inhalation |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
AR036358A1 (es) | 2001-08-28 | 2004-09-01 | Schering Corp | Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma |
GB0201400D0 (en) | 2002-01-22 | 2002-03-13 | Glaxo Group Ltd | Novel apparatus and process |
ME00077B (me) | 2002-03-01 | 2010-06-10 | Chiesi Farm Spa | Formoterol najfiniji preparat |
GB0207899D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and cielesonide aerosol formulations |
US7582284B2 (en) | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
RU2327450C2 (ru) * | 2002-08-29 | 2008-06-27 | Сипла Лимитед | Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды |
US20060193610A1 (en) | 2003-07-12 | 2006-08-31 | Jong-Hun Han | Aromatic emitting apparatus for using cigarjack |
JP2007505921A (ja) | 2003-09-19 | 2007-03-15 | ペンウェスト ファーマシューティカルズ カンパニー | 遅延放出剤形 |
GB0323685D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
EP1811981B1 (en) * | 2004-10-12 | 2008-08-13 | Merck Generics (UK) Limited | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister |
GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
GB0918150D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
JP2015036045A (ja) * | 2013-08-12 | 2015-02-23 | 株式会社泉技研 | 骨質改善のための超音波音響システム及び超音波音響機器の作動方法 |
JP6135815B1 (ja) | 2016-09-29 | 2017-05-31 | 東洋インキScホールディングス株式会社 | プリント配線板および電子機器 |
-
2009
- 2009-10-16 GB GBGB0918149.6A patent/GB0918149D0/en not_active Ceased
-
2010
- 2010-10-15 RS RS20240366A patent/RS65391B1/sr unknown
- 2010-10-15 BR BR112012008983A patent/BR112012008983A2/pt not_active Application Discontinuation
- 2010-10-15 PL PL10768922T patent/PL2488158T3/pl unknown
- 2010-10-15 DK DK10768922T patent/DK2488158T3/en active
- 2010-10-15 NZ NZ599901A patent/NZ599901A/xx unknown
- 2010-10-15 AU AU2010305698A patent/AU2010305698C9/en active Active
- 2010-10-15 CN CN201080046310.7A patent/CN102665675B/zh active Active
- 2010-10-15 PT PT10768922T patent/PT2488158E/pt unknown
- 2010-10-15 JP JP2012533650A patent/JP2013507430A/ja active Pending
- 2010-10-15 PT PT141998815T patent/PT2881108T/pt unknown
- 2010-10-15 SI SI201030889T patent/SI2488158T1/sl unknown
- 2010-10-15 EP EP23219752.5A patent/EP4327807A3/en active Pending
- 2010-10-15 CA CA2776359A patent/CA2776359C/en active Active
- 2010-10-15 WO PCT/EP2010/065573 patent/WO2011045432A1/en active Application Filing
- 2010-10-15 DK DK14199881.5T patent/DK2881108T3/da active
- 2010-10-15 LT LTEP14199881.5T patent/LT2881108T/lt unknown
- 2010-10-15 ES ES10768922.6T patent/ES2533372T3/es active Active
- 2010-10-15 MX MX2012004337A patent/MX2012004337A/es active IP Right Grant
- 2010-10-15 EP EP14199881.5A patent/EP2881108B1/en active Active
- 2010-10-15 SI SI201032141T patent/SI2881108T1/sl unknown
- 2010-10-15 FI FIEP14199881.5T patent/FI2881108T3/fi active
- 2010-10-15 RS RS20150160A patent/RS53883B1/en unknown
- 2010-10-15 US US13/503,245 patent/US20120282189A1/en not_active Abandoned
- 2010-10-15 EP EP10768922.6A patent/EP2488158B1/en not_active Revoked
-
2012
- 2012-04-04 ZA ZA2012/02452A patent/ZA201202452B/en unknown
- 2012-04-13 CL CL2012000947A patent/CL2012000947A1/es unknown
- 2012-04-15 IL IL219161A patent/IL219161B/en active IP Right Grant
-
2013
- 2013-01-09 HK HK13100348.4A patent/HK1173077A1/xx not_active IP Right Cessation
-
2014
- 2014-05-16 US US14/279,751 patent/US20140314684A1/en not_active Abandoned
-
2015
- 2015-02-16 HR HRP20150174TT patent/HRP20150174T1/hr unknown
- 2015-02-26 JP JP2015036045A patent/JP2015129162A/ja active Pending
- 2015-03-06 SM SM201500052T patent/SMT201500052B/xx unknown
- 2015-03-13 CY CY20151100253T patent/CY1116109T1/el unknown
- 2015-12-03 HK HK15111930.3A patent/HK1211207A1/xx unknown
-
2016
- 2016-09-14 US US15/265,467 patent/US10471077B2/en active Active
- 2016-12-27 JP JP2016252909A patent/JP6568511B2/ja active Active
-
2019
- 2019-08-02 JP JP2019142684A patent/JP7203701B2/ja active Active
-
2022
- 2022-12-27 JP JP2022209895A patent/JP2023026517A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS52940B (en) | PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS | |
PE20140101A1 (es) | Formulacion para inhalacion que comprende aclidinio | |
BR112012015337B8 (pt) | composição farmacêutica, cartucho de aerossol, método para carregar um cartucho de aerossol, conjunto de componentes e uso de uma composição farmacêutica | |
CL2012000947A1 (es) | Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis. | |
ECSP088653A (es) | Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva | |
BRPI0607574A2 (pt) | composição farmacêutica aerossol | |
PE20141036A1 (es) | Nueva dosificacion y formulacion | |
AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
PE20080204A1 (es) | Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista | |
BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
GB0323684D0 (en) | Improvements in or relating to organic compounds | |
WO2011076841A3 (en) | Combination therapy for copd | |
AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
MX336225B (es) | Composiciones que comprenden sulfato de salbutamol. | |
NZ599900A (en) | Pharmaceutical suspension aerosol formulations for use in metered dose inhalers | |
PE20070353A1 (es) | Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol | |
CL2014003211A1 (es) | Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende | |
NI201400139A (es) | Nueva forma de dosificación y formulación de abediterol | |
CL2023000998A1 (es) | Formulación farmacéutica para inhalador presurizado de dosis medidas | |
NO20083759L (no) | Doserings aerosoler for administrering av farmasoytiske preparater | |
CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
TNSN07289A1 (en) | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent | |
UY28096A1 (es) | Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación | |
BR102012008322B8 (pt) | formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa | |
TH66681A (th) | สูตรผสมที่ละเอียดเป็นพิเศษของฟอร์มอเทอรอล |